Jemonda-S XR 500 Tablet is a fixed-dose combination medication containing Dapagliflozin 10 mg, Metformin 500 mg, and Sitagliptin 100 mg, indicated for the management of type 2 diabetes mellitus. This formulation combines three antihyperglycemic agents with complementary mechanisms of action to improve glycemic control. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promotes renal glucose excretion, thereby reducing plasma glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which in turn stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The extended-release (XR) formulation ensures sustained drug delivery, enhancing patient compliance and maintaining stable plasma drug concentrations. Jemonda-S XR 500 is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. It is essential to monitor renal function prior to initiation and periodically during treatment due to the risk of lactic acidosis associated with Metformin and potential renal effects of Dapagliflozin. Common adverse effects may include urinary tract infections, gastrointestinal disturbances, and hypoglycemia when used in combination with other antidiabetic agents. Use with caution in patients with renal impairment, and contraindicated in those with type 1 diabetes or diabetic ketoacidosis.